BioSpace Movers and Shakers: March 29
Epic Sciences – San Diego-based Epic Sciences named Lloyd Sanders as its newest president and chief executive officer. Sanders takes over for Murali Prahalad, who has left the company after six years at the helm to pursue new opportunities. Sanders joins Epic with 20 years of diagnostics and pharmaceutical industry experience, much of it focused on oncology. Prior to Epic, Sanders served as president of the oncology segment of Myriad Genetics. There, he oversaw the oncology, urology and dermatology commercial organizations. Previously, Sanders served as chief operating officer at Dey Pharma, a division of Mylan. He also held several leadership positions at Sanofi-Aventis and Pfizer.
Enterprise Therapeutics – Arena Pharmaceuticals CEO Amit D. Munshi was named a Non-Executive Chairman of the Board of Directors at U.K.-based Enterprise Therapeutics. Munshi has more than 28 years of global biopharmaceutical industry experience in executive management, business development, product development and portfolio management, and has served on several private and public company boards. Previously, Munshi served as president and CEO of Epirus Biopharmaceuticals, Inc. and Percivia LLC. Prior to Epirus and Percivia, he was a co-founder and chief business officer of Kythera Biopharmaceuticals, Inc., and held multiple leadership positions at Amgen
Sphere Fluidics -- Sphere Fluidics, a company commercializing single cell analysis systems, is expanding its headcount. The company named Rob Treanor and Andrew Campbell as director of operations and director of finance, respectively. Additionally, the Cambridge, England company added new hires to its sales, operations and scientific teams. These appointments will expand the Company’s commercial capabilities and facilitate service and support for new and existing Cyto-Mine customers in both the U.K. and U.S. Treanor has extensive experience running large logistics and supply teams within the biotechnology sector. Campbell previously held senior positions at various global Life Sciences companies including, Charles Rivers and Perkin Elmer Life Sciences. The company also made key appointments to its U.S. field applications and Service Engineering teams to expand services and support for new and existing customers across North America. Additionally, hires in marketing, product management and sales have been made.
Seven Bridges Genomics – Boston-based Seven Bridges made two key leadership appointments. The company named William Moss as its new CEO and Brandi Davis-Dusenbery as the new chief scientific officer. Moss previously served as chief operations officer and president of commercial operations at Seven Bridges. During his tenure at the company, Moss has been instrumental in facilitating the development of the company's newly honed biopharma corporate strategy, Seven Bridges said. Davis-Dusenbery is Seven Bridges first CSO. In this role, she will oversee all aspects of scientific innovation, solution strategy, bioinformatics expertise, and a portfolio of programs focused on making biomedical data more findable, interoperable, accessible and reusable.
Dermavant Sciences – Roivant subsidiary Dermavant tapped Cyril Allouche as its new CFO. He most recently served as principal accounting officer, head of finance and corporate controller at Revance Therapeutics. Prior to Revance, Allouche held finance leadership roles at CareDx, Inc. and Synnex Corp. He also spent over a decade at PricewaterhouseCoopers.
Provention Bio – New Jersey-based Provention Bio appointed Jeffrey Bluestone to the company’s board of directors. Currently, Bluestone is the president and CEO of the Parker Institute for Cancer Immunotherapy. He was the founding director of the Immune Tolerance Network, the largest NIH-funded multicenter clinical immunology research program. Bluestone was also appointed by former Vice President Joe Biden as a member of the Blue Ribbon Panel of scientific experts to guide the National Cancer Moonshot Initiative and also served as a senior investigator at the National Cancer Institute of the National Institutes of Health. His research has led to the development and commercialization of multiple immunotherapies, including the first FDA-approved drug targeting T-cell co-stimulation to treat autoimmune disease and organ transplantation and the first CTLA-4 antagonist drugs approved by the FDA for the treatment of metastatic melanoma.
Axcella -- Shreeram Aradhye was named chief development officer of Cambridge, Mass.-based Axcella Health. Aradhye brings more than 20 years of pharmaceutical industry experience in clinical development and medical affairs to Axcella, most recently as CMO and Global Head of Medical Affairs for Novartis Pharmaceuticals. Axcella also announced the appointment of Karen Lewis as senior vice president of Human Resources. She most recently led the Global Talent Acquisition organization at Biogen.
InteRNA Technologies – Netherlands-based InteRNA tapped Andrea van Elsas for the company’s Scientific Advisory Board. van Elsas is an immuno-oncology expert with over 20 years of and currently serves as Chief Scientific Officer of Aduro Biotech. Prior to his role as CSO of Aduro Biotech, van Elsas was CSO of Aduro Biotech Europe from 2015 to 2017. He joined Aduro following the 2015 acquisition of BioNovion, where he served as CSO.
Imara – Willem H. Scheele was named chief medical officer of Cambridge, Mass.-based Imara Inc. As CMO, Scheele will guide the advancement of Imara’s IMR-687, currently in a Phase IIa clinical trial for the treatment of sickle cell disease, and manage the strategy of the company’s overall clinical drug development efforts. Scheele replaces interim CMO Shi Yin Foo. Prior to joining Imara, Scheele was executive director and clinician group lead of rare diseases for Pfizer. Prior to that role, he was also senior director of global innovative pharma, medicines development at Pfizer. Earlier in his career, Scheele was director of Women’s Health and Bone associate clinical research physician at Eli Lilly.
Evaluate Ltd. -- Deborah Kobewka was named CEO of Evaluate Ltd. She succeeds Alex Karle, who joined Evaluate in 2012 as COO before assuming the role of CEO in 2014. Kobewka joins Evaluate from the Department for International Trade in the U.K. government where she served as Managing Director of Healthcare UK, Lifesciences and Bio-economy.
Schrodinger – New York-based Schrödinger tapped Brian Shoichet for its scientific advisory board. Shoichet currently serves in the Department of Pharmaceutical Chemistry at the University of California, San Francisco.
Know about someone making a big move in the life sciences industry? Send editorial suggestions to email@example.com for inclusion in our Friday Movers and Shakers roundup. Looking to make a move yourself? Check out BioSpace’s job board for thousands of the latest life sciences jobs.